
News|Videos|December 9, 2020
The Most Interesting Results from the RESET Clinical Trial
In an interview with Pharmacy Times, Helen Thackray, MD, reveals what finding she believes was the most interesting after analyzing the results of the RESET clinical trial, which covers the early initiation with rivipansel for acute vaso-occulusive crisis in sickle cell disease.
Advertisement
In an interview with Pharmacy Times, Helen Thackray, MD, reveals what finding she believes was the most interesting after analyzing the results of the RESET clinical trial, which covers the early initiation with rivipansel for acute vaso-occulusive crisis in sickle cell disease. This study was presented at the 62nd ASH Annual Meeting and Exposition.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
The Peptide Reclassification Everyone's Talking About: A Pharmacist's Take on What RFK Jr's Announcement Actually Means
2
Subcutaneous Isatuximab On-Body Injector Shows High Reliability, Favorable Safety Across Multiple Myeloma Trials
3
Real-World Use of Talazoparib Plus Enzalutamide and HR Testing Trends in Prostate Cancer
4
Brain Inflammation May Not Drive Persistent Long COVID Symptoms, New Imaging Study Finds
5




























































































































